Eli Lilly Plummets On Rare — But 'Big' — Sales Miss For Diabetes, Weight-Loss Drugs

Eli Lilly Plummets On Rare — But 'Big' — Sales Miss For Diabetes, Weight-Loss Drugs · Investor's Business Daily
ALLISON GATLIN
2 min read

In This Article:

Eli Lilly stock crashed Wednesday after the pharma giant cut its 2024 outlook following a "big" miss for its diabetes and weight-loss drugs.

Recommended Stories